NCT06961201View on ClinicalTrials.gov

Nano-crystalline Megestrol Acetate Combined With Standard Treatment Versus Standard Treatment for First-line Extensive-stage Small Cell Lung Cancer in the Cachexia Phase

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

94

Participants

Timeline

Start Date

May 1, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

June 30, 2027

Conditions
Extensive-stage Small Cell Lung Cancer (ES-SCLC)The Pre-cachexia or Cachexia Patients Who Have Not Received Systemic Treatment and Are Not Eligible for Curative Therapy
Interventions
DRUG

Nano-crystalline Megestrol Acetate Oral Suspension

Nano-crystalline Megestrol Acetate Oral Suspension, with a specification of 125 mg/mL, the study group takes 5 mL orally per day (625 mg/day), and continues medication.

DRUG

standard treatment

standard treatment

Trial Locations (1)

610000

West China School of Medicine/West China Hospital of Sichuan University, Chengdu

All Listed Sponsors
collaborator

West China Hospital

OTHER

lead

Changchun GeneScience Pharmaceutical Co., Ltd.

INDUSTRY